These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19625640)

  • 41. HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen.
    Wang Q; Dai Y; Sun Z; Su X; Yu Y; Hua C; Xu W; Jiang S; Lu L
    Emerg Microbes Infect; 2017 Nov; 6(11):e102. PubMed ID: 29184156
    [No Abstract]   [Full Text] [Related]  

  • 42. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates.
    Yoshino N; Lü FX; Fujihashi K; Hagiwara Y; Kataoka K; Lu D; Hirst L; Honda M; van Ginkel FW; Takeda Y; Miller CJ; Kiyono H; McGhee JR
    J Immunol; 2004 Dec; 173(11):6850-7. PubMed ID: 15557179
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial.
    Kahn JO; Steimer KS; Baenziger J; Duliege AM; Feinberg M; Elbeik T; Chesney M; Murcar N; Chernoff D; Sinangil F
    J Infect Dis; 1995 May; 171(5):1343-7. PubMed ID: 7751714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [VLP vaccines and effects of HIV-1 Env protein modifications on their antigenic properties].
    Vzorov AN; Compans RW
    Mol Biol (Mosk); 2016; 50(3):406-15. PubMed ID: 27414779
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
    AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIV(KU2) infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail.
    Nehete PN; Nehete BP; Hill L; Manuri PR; Baladandayuthapani V; Feng L; Simmons J; Sastry KJ
    Virology; 2008 Jan; 370(1):130-41. PubMed ID: 17920095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.
    Virnik K; Nesti E; Dail C; Scanlan A; Medvedev A; Vassell R; McGuire AT; Stamatatos L; Berkower I
    Vaccine; 2018 Aug; 36(34):5166-5172. PubMed ID: 30037665
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01
    Van Der Meeren O; Jongert E; Seaton KE; Koutsoukos M; Aerssens A; Brackett C; Debois M; Janssens M; Leroux-Roels G; Mesia Vela D; Sawant S; Yates NL; Tomaras GD; Leroux-Roels I; Roman F
    Vaccine; 2020 Feb; 38(7):1678-1689. PubMed ID: 31932137
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand.
    Sailaja G; Husain S; Nayak BP; Jabbar AM
    J Immunol; 2003 Mar; 170(5):2496-507. PubMed ID: 12594275
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination.
    Locher CP; Grant RM; Collisson EA; Reyes-Terán G; Elbeik T; Kahn JO; Levy JA
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1685-9. PubMed ID: 10606091
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.
    Connor RI; Korber BT; Graham BS; Hahn BH; Ho DD; Walker BD; Neumann AU; Vermund SH; Mestecky J; Jackson S; Fenamore E; Cao Y; Gao F; Kalams S; Kunstman KJ; McDonald D; McWilliams N; Trkola A; Moore JP; Wolinsky SM
    J Virol; 1998 Feb; 72(2):1552-76. PubMed ID: 9445059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.
    Balasubramanian P; Kumar R; Williams C; Itri V; Wang S; Lu S; Hessell AJ; Haigwood NL; Sinangil F; Higgins KW; Liu L; Li L; Nyambi P; Gorny MK; Totrov M; Nadas A; Kong XP; Zolla-Pazner S; Hioe CE
    Vaccine; 2017 Mar; 35(10):1464-1473. PubMed ID: 28185743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.
    Williams WB; Liao HX; Moody MA; Kepler TB; Alam SM; Gao F; Wiehe K; Trama AM; Jones K; Zhang R; Song H; Marshall DJ; Whitesides JF; Sawatzki K; Hua A; Liu P; Tay MZ; Seaton KE; Shen X; Foulger A; Lloyd KE; Parks R; Pollara J; Ferrari G; Yu JS; Vandergrift N; Montefiori DC; Sobieszczyk ME; Hammer S; Karuna S; Gilbert P; Grove D; Grunenberg N; McElrath MJ; Mascola JR; Koup RA; Corey L; Nabel GJ; Morgan C; Churchyard G; Maenza J; Keefer M; Graham BS; Baden LR; Tomaras GD; Haynes BF
    Science; 2015 Aug; 349(6249):aab1253. PubMed ID: 26229114
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
    Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC
    J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunologic mechanism for human immunodeficiency virus type 1 gp120 vaccine failure.
    O'Toole C; Müller S; Nara P; Köhler H
    J Infect Dis; 1996 Feb; 173(2):512-3. PubMed ID: 8568327
    [No Abstract]   [Full Text] [Related]  

  • 59. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
    Akapirat S; Karnasuta C; Vasan S; Rerks-Ngarm S; Pitisuttithum P; Madnote S; Savadsuk H; Rittiroongrad S; Puangkaew J; Phogat S; Tartaglia J; Sinangil F; de Souza MS; Excler JL; Kim JH; Robb ML; Michael NL; Ngauy V; O'Connell RJ; Karasavvas N;
    PLoS One; 2018; 13(4):e0196397. PubMed ID: 29702672
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
    Thongcharoen P; Suriyanon V; Paris RM; Khamboonruang C; de Souza MS; Ratto-Kim S; Karnasuta C; Polonis VR; Baglyos L; Habib RE; Gurunathan S; Barnett S; Brown AE; Birx DL; McNeil JG; Kim JH;
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):48-55. PubMed ID: 17909315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.